프로티아
Financials
Valuation Metrics
프로티아's Market Cap is ₩679B. At end of 2025 it was ₩804B. Ranked #1568 of 2,421 in KR market (top 65%), #924 of 1,640 on KOSDAQ (top 56%), #61 of 96 in Health Care Equipment & Services (top 64%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 67.88B KRW | KR#1,568/2,421 Sec#61/96 |
| Revenue | 17.75B KRW | KR#2,174/2,421 Sec#73/96 |
| Net Income | 5.50B KRW | KR#1,168/2,421 Sec#37/96 |
| Total Assets | 33.03B KRW | KR#2,318/2,421 Sec#85/96 |
| Net Assets | 30.70B KRW | KR#2,168/2,421 Sec#77/96 |
| Employees | 89 | KR#1,732/2,421 Sec#68/96 |
| Value | ||
| P/E | 12.34x | KR#945/2,421 Sec#29/96 |
| P/B | 2.21x | KR#1,993/2,421 Sec#71/96 |
| PEG | 0.13x | KR#470/2,421 Sec#21/96 |
| P/S | 3.82x | KR#2,073/2,421 Sec#68/96 |
| EV/EBITDA | 13.92x | KR#816/2,421 Sec#26/96 |
| FCF Yield | 4.43% | KR#888/2,421 Sec#23/96 |
| Profitability | ||
| ROE | 17.91% | KR#213/2,421 Sec#8/96 |
| ROA | 16.65% | KR#84/2,421 Sec#5/96 |
| Op. Margin | 26.27% | KR#84/2,421 Sec#5/96 |
| Revenue Growth | 42.75% | KR#258/2,421 Sec#13/96 |
| Earnings Growth | 92.23% | KR#412/2,421 Sec#20/96 |
| Financial Health | ||
| Debt Ratio | 7.60% | KR#81/2,421 Sec#5/96 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/96 |
| FCF | 3.00B KRW | KR#1,020/2,421 Sec#29/96 |
| Cash | 2.96B KRW | KR#2,166/2,421 Sec#87/96 |
| Current Ratio | 14.79x | KR#50/2,421 Sec#6/96 |
| Net Debt/EBITDA | -0.64x | KR#458/2,421 Sec#16/96 |
| Performance | ||
| 1Y Return | 3.54% | KR#664/2,421 Sec#17/96 |
| 1M Return | 10.95% | KR#454/2,421 Sec#12/96 |
| From 52W High | -23.51% | KR#346/2,421 Sec#9/96 |
| 1Y MDD | -42.06% | KR#661/2,421 Sec#21/96 |
| Trading | ||
| Volume | 6,577 shares | KR#2,053/2,421 Sec#84/96 |
| Trading Value | 34.7M KRW | KR#1,967/2,421 Sec#79/96 |
| Foreign Own. | 2.03% | KR#1,617/2,421 Sec#60/96 |
| Per Share | ||
| EPS | 427 KRW | KR#1,053/2,421 Sec#31/96 |
| BPS | 2,383 KRW | KR#1,983/2,421 Sec#63/96 |
Company Info
Protia, established in 2000 and transferred its listing to the KOSDAQ Market in 2023, develops, manufactures, and sells medical devices based on core immunodiagnostic technology. The company produces and supplies human-use products with the world's highest number of simultaneous allergy diagnostic technologies, the first domestic pet products, and the first antibiotic susceptibility testing products utilizing a capacitance measurement method. Protia possesses development capabilities for 192-line allergy diagnostic products and pursues technological innovation by expanding into domestic and international markets. Protia is headquartered in Gangseo-gu, Seoul.